United Therapeutics Corporation $UTHR Shares Acquired by Sei Investments Co.

Sei Investments Co. increased its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 5.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 28,421 shares of the biotechnology company’s stock after buying an additional 1,589 shares during the period. Sei Investments Co.’s holdings in United Therapeutics were worth $16,853,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in UTHR. Lido Advisors LLC grew its stake in shares of United Therapeutics by 156.7% during the first quarter. Lido Advisors LLC now owns 1,653 shares of the biotechnology company’s stock valued at $981,000 after acquiring an additional 1,009 shares in the last quarter. Cetera Investment Advisers boosted its holdings in United Therapeutics by 4.1% in the first quarter. Cetera Investment Advisers now owns 8,648 shares of the biotechnology company’s stock valued at $5,128,000 after purchasing an additional 338 shares during the last quarter. First Trust Advisors LP grew its stake in United Therapeutics by 23.5% during the 1st quarter. First Trust Advisors LP now owns 270,578 shares of the biotechnology company’s stock valued at $160,447,000 after purchasing an additional 51,555 shares in the last quarter. ABN Amro Investment Solutions grew its stake in United Therapeutics by 8.3% during the 1st quarter. ABN Amro Investment Solutions now owns 1,889 shares of the biotechnology company’s stock valued at $1,120,000 after purchasing an additional 144 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in United Therapeutics by 16.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,397 shares of the biotechnology company’s stock worth $2,607,000 after purchasing an additional 621 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Up 0.2%

NASDAQ:UTHR opened at $524.70 on Thursday. The company has a market cap of $22.27 billion, a PE ratio of 19.37, a P/E/G ratio of 1.75 and a beta of 0.58. The business’s 50 day moving average is $545.45 and its two-hundred day moving average is $532.24. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the firm posted $6.63 earnings per share. As a group, sell-side analysts expect that United Therapeutics Corporation will post 26.65 EPS for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $578.58, for a total transaction of $5,785,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,921,276.08. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 502,833 shares of company stock valued at $279,835,157 over the last three months. Insiders own 8.60% of the company’s stock.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Promising ralinepag trial results: The Lancet published full results from United Therapeutics’ ADVANCE OUTCOMES study. Investigational pulmonary arterial hypertension treatment ralinepag reduced the risk of clinical worsening by 55% versus placebo, improving the company’s potential pipeline outlook. Ralinepag is not yet approved by the FDA, so regulatory and commercialization risks remain. United Therapeutics Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
• Positive Sentiment: Analyst support remains strong: Eleven analysts rate UTHR a Buy and two rate it a Hold, producing a consensus “Moderate Buy” rating. The average price target is $648.33, with JPMorgan recently raising its target to $687 and HC Wainwright increasing its target to $660. United Therapeutics Given Average Rating of Moderate Buy by Brokerages
• Neutral Sentiment: Institutional ownership is high: Hedge funds and other institutional investors own approximately 94.1% of UTHR’s shares. Several institutions increased their positions during the second quarter, signaling continued professional-investor interest, although this does not guarantee further gains. United Therapeutics Insider Trading Report
• Negative Sentiment: CEO stock sale may pressure sentiment: CEO Martine Rothblatt sold 9,500 shares for roughly $5.04 million, reducing her direct stake by 2.84%. She still owns a substantial position, so the transaction may reflect liquidity or diversification rather than a negative view of the business, but insider selling can weigh on investor confidence. Insider Selling United Therapeutics CEO Sells Stock
• Negative Sentiment: Recent operating results were below expectations: United Therapeutics previously reported quarterly earnings and revenue below consensus, with revenue declining 1.6% year over year. That performance remains a concern despite the company’s strong profitability and promising pipeline.

Analysts Set New Price Targets

UTHR has been the topic of a number of recent analyst reports. Morgan Stanley set a $516.00 target price on United Therapeutics in a research report on Thursday, May 7th. Royal Bank Of Canada lifted their price target on shares of United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. JPMorgan Chase & Co. increased their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Finally, Raymond James Financial initiated coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $648.33.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.